Full Press Release Details
Phone: (410) 269-2610
PHARMATHENE REPORTS SECOND QUARTER 2014
FINANCIAL AND OPERATIONAL RESULTS
ANNAPOLIS, MD - August 4, 2014
- PharmAthene, Inc. (NYSE MKT: PIP), a biodefense company developing medical countermeasures against biological and
chemical threats, today reported its financial and operational results for the second quarter of 2014.
For the three months ended June 30, 2014,
PharmAthene recognized revenue of approximately $3.7 million, compared to approximately $4.3 million for the corresponding period
in 2013. Revenue was derived primarily from contracts with the U.S. government for the development of the Company's biodefense
product candidates. The decrease in revenue in the second quarter of 2014 reflects an overall reduction in development activity
in the Company's biodefense programs, including the de-scoping of the current SparVax anthrax vaccine contract.
Research and development expenses in the
second quarter of 2014 were approximately $2.4 million, compared to approximately $3.4 million for the corresponding period in
2013. The decrease in research and development expenses during the current period resulted primarily from reduced activity under
the Company's biodefense contracts.
Expenses associated with general and administrative
functions were approximately $2.4 million in the second quarter of 2014, compared to approximately $2.3 million for the same period
For the second quarter of 2014, PharmAthene's
net loss was $0.4 million, or $0.01 per share, compared to a net loss of $1.2 million, or $0.02 per share, for the corresponding
At June 30, 2014, PharmAthene had cash
and cash equivalents totaling approximately $11.3 million, compared to approximately $10.5 million at December 31, 2013. U.S. government
billed and unbilled accounts receivable totaled approximately $0.6 million at June 30, 2014, compared to approximately $3.6 million
at December 31, 2013. The decrease in receivables in the second quarter of 2014 is a result of reduced development activity in
the Company's biodefense programs, as discussed above. The sum total of cash and cash equivalents and U.S. government accounts
receivable at June 30, 2014 was approximately $11.9 million, compared to approximately $14.1 million at December 31, 2013.
Eric I. Richman, President and Chief Executive
Officer, commented, "As a result of the recent de-scoping and partial termination for convenience of our SparVax
contract, we implemented a corporate downsizing in July of 2014. The reduction in force supports our efforts to carefully manage
our cash utilization while we pursue other funding opportunities for the SparVax program, and await a ruling from
the Delaware Court of Chancery regarding the current litigation with SIGA Technologies, Inc."
PharmAthene is a leading biodefense company
engaged in the development and commercialization of next generation medical countermeasures against biological and chemical threats.
PharmAthene's current biodefense portfolio includes the following product candidates:
In addition, in May 2013, the Delaware
Supreme Court issued its ruling on the appeal in our litigation with SIGA Technologies, affirming the Court of Chancery's
finding that SIGA was liable for breach of contract, reversing its finding of promissory estoppel, and remanding the case to the
Court of Chancery to reconsider the appropriate remedy and award of attorney's fees and expert witness costs in light of
the Supreme Court's opinion. For more information about PharmAthene, please visit www.PharmAthene.com.
Forward-Looking Statement Disclaimer
Except for the historical information presented
herein, matters discussed may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform
Act of 1995 that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future
results, performance or achievements expressed or implied by such statements. Statements that are not historical facts, including
statements preceded by, followed by, or that include the words "will"; "potential"; "believe";
"anticipate"; "look forward"; "intend"; "plan"; "expect"; "estimate";
"could"; "may"; "should"; or similar statements are forward-looking statements. Such statements
include, but are not limited to those referring to potential future government contracts or grant awards; potential payments under
government contracts or grants; specifically those referring to the de-scoping and partial termination of the current SparVax
anthrax vaccine contract; the outcome of the SIGA litigation; and our ability to deploy our resources. PharmAthene disclaims
any intent or obligation to update these forward-looking statements. Risks and uncertainties include, among others, risks associated
with the reliability of the results of the studies relating to human safety and possible adverse effects resulting from the company's
product candidates; unexpected funding delays and/or reductions or elimination of U.S. government funding for one or more of the
company's development programs; awards of government contracts to our competitors; unforeseen safety issues; unexpected determinations
that our product candidates prove not to be effective and/or capable of being marketed as products; as well as risks detailed from
time to time in PharmAthene's Annual Reports on Form 10-K and quarterly reports on Form 10-Q under the caption "Risk Factors"
and in its other reports filed with the U.S. Securities and Exchange Commission. In particular, there is significant uncertainty
regarding the level and timing of sales of Tecovirimat, also known as ST 246 (formerly referred to as "Arestvyr "
and currently referred to by SIGA as "Tecovirimat") and whether and when it will be approved by the U.S. FDA and corresponding
health agencies around the world. PharmAthene cannot predict with certainty the timing, amount and profitability thereof or its
ability to collect any such amounts, and there can be no assurance that any profits received from SIGA will be significant or if
the Court of Chancery will award any portion of the profits to PharmAthene. In its May 2013 decision, the Delaware Supreme Court
reversed the remedy ordered by the Delaware Court of Chancery and remanded the issue of a remedy back to the trial court for reconsideration
in light of the Delaware Supreme Court's opinion. As a result, there can be no assurance that the Delaware Court of Chancery
will issue a remedy that provides PharmAthene with a financial interest in Tecovirimat and related products or any remedy.
In addition, significant additional research work, non-clinical animal studies, clinical trial, and manufacturing development work
remains to be done with respect to PharmAthene's product candidates. At this point, there can be no assurance that any of
these product candidates will be shown to be safe and effective and approved by regulatory authorities for use in humans. Copies
of PharmAthene's public disclosure filings are available from its investor relations department and its website under the investor
relations tab at www.pharmathene.com.
| PHARMATHENE, INC. | ||||||||
| CONDENSED CONSOLIDATED BALANCE SHEETS | ||||||||
| June 30, | December 31, | |||||||
| 2014 | 2013 | |||||||
| (Unaudited) | ||||||||
| ASSETS | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 11,265,082 | $ | 10,480,979 | ||||
| Billed accounts receivable | - | 1,427,113 | ||||||
| Unbilled accounts receivable | 617,396 | 2,199,525 | ||||||
| Prepaid expenses and other current assets | 550,979 | 231,491 | ||||||
| Total current assets | 12,433,457 | 14,339,108 | ||||||
| Property and equipment, net | 386,541 | 386,068 | ||||||
| Other long-term assets and deferred costs | 55,032 | 65,660 | ||||||
| Goodwill | 2,348,453 | 2,348,453 | ||||||
| Total assets | $ | 15,223,483 | $ | 17,139,289 | ||||
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 437,382 | $ | 1,128,172 | ||||
| Accrued expenses and other liabilities | 1,393,856 | 3,182,687 | ||||||
| Deferred revenue | - | 341,723 | ||||||
| Current portion of long-term debt | 999,996 | 999,996 | ||||||
| Current portion of derivative instruments | 4 | 51,663 | ||||||
| Short-term debt | - | 1,091,740 | ||||||
| Total current liabilities | 2,831,238 | 6,795,981 | ||||||
| Other long-term liabilities | 572,854 | 588,745 | ||||||
| Long-term debt, less current portion | 239,738 | 730,279 | ||||||
| Derivative instruments, less current portion | 715,041 | 1,688,572 | ||||||
| Total liabilities | 4,358,871 | 9,803,577 | ||||||
| Stockholders' equity: | ||||||||
| Common stock, $0.0001 par value; 100,000,000 shares authorized; 55,525,710 and 52,304,246 shares issued and outstanding at June 30, 2014 and December 31, 2013, respectively | 5,553 | 5,230 | ||||||
| Additional paid-in-capital | 224,104,547 | 217,877,117 | ||||||
| Accumulated other comprehensive loss | (220,003 | ) | (218,710 | ) | ||||
| Accumulated deficit | (213,025,485 | ) | (210,327,925 | ) | ||||
| Total stockholders' equity | 10,864,612 | 7,335,712 | ||||||
| Total liabilities and stockholders' equity | $ | 15,223,483 | $ | 17,139,289 |
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
| Three months ended June 30, | Six months ended June 30, | |||||||||||||||
| 2014 | 2013 | 2014 | 2013 | |||||||||||||
| Contract revenue | $ | 3,658,933 | $ | 4,295,400 | $ | 7,401,458 | $ | 10,770,538 | ||||||||
| Operating expenses: | ||||||||||||||||
| Research and development | 2,372,687 | 3,402,545 | 5,799,687 | 8,636,020 | ||||||||||||
| General and administrative | 2,419,909 | 2,332,730 | 5,097,361 | 4,612,525 | ||||||||||||
| Depreciation | 36,208 | 41,854 | 76,147 | 94,456 | ||||||||||||
| Total operating expenses | 4,828,804 | 5,777,129 | 10,973,195 | 13,343,001 | ||||||||||||
| Loss from operations | $ | (1,169,871 | ) | $ | (1,481,729 | ) | $ | (3,571,737 | ) | $ | (2,572,463 | ) | ||||
| Other income (expense): | ||||||||||||||||
| Interest income | 676 | 1,656 | 682 | 2,439 | ||||||||||||
| Interest expense | (57,230 | ) | (100,027 | ) | (127,108 | ) | (199,818 | ) | ||||||||
| Change in fair value of derivative instruments | 782,549 | 352,824 | 1,025,190 | (552,953 | ) | |||||||||||
| Other income (expense) | (1,912 | ) | 2,110 | (1,550 | ) | (4,013 | ) | |||||||||
| Total other income (expense) | 724,083 | 256,563 | 897,214 | (754,345 | ) | |||||||||||
| Net loss before income taxes | (445,788 | ) | (1,225,166 | ) | (2,674,523 | ) | (3,326,808 | ) | ||||||||
| Income tax (provision) benefit | 6,668 | (11,206 | ) | (23,037 | ) | (20,949 | ) | |||||||||
| Net loss | $ | (439,120 | ) | $ | (1,236,372 | ) | $ | (2,697,560 | ) | $ | (3,347,757 | ) | ||||
| Basic and diluted net loss per share | $ | (0.01 | ) | $ | (0.02 | ) | $ | (0.05 | ) | $ | (0.07 | ) | ||||
| Weighted average shares used in calculation of basic and diluted net loss per share | 54,670,870 | 49,749,167 | 53,861,988 | 49,058,014 |
The accompanying notes are an integral part of the unaudited condensed consolidated financial statements.